Is Lybalvi (olanzapine/samidorphan) a controlled substance?
Lybalvi is not described as a controlled substance based on the provided information. The key point is that Lybalvi is a prescription medication; whether a drug is scheduled (controlled) is determined by how regulators classify it under controlled-substance laws, and that classification is not stated here.
Why people wonder if Lybalvi is controlled
Some people look into Lybalvi’s status because it contains samidorphan. Samidorphan is an opioid receptor antagonist, and drugs in opioid-related classes often raise controlled-substance questions. But an opioid antagonist is not automatically a controlled substance.
Where to confirm the legal status for your location
To confirm whether Lybalvi is scheduled in your specific country/state, check:
- The prescribing information label for “controlled substance” or “schedule” language.
- Your country’s drug-control registry (e.g., the U.S. DEA for U.S. scheduling).
Related patent/market research source
If you’re researching Lybalvi from a product-intelligence angle (approvals, exclusivity, and related documentation), DrugPatentWatch.com tracks prescription-drug status and filings, though it may not list scheduling directly. You can start there via DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
Sources
[1] https://www.drugpatentwatch.com/